Sign Up to like & get recommendations! 2
Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.52140
Abstract: This case series examines transcriptomic factors associated with outcomes in patients with rectal cancer who received neoadjuvant chemoradiotherapy. read more here.
Sign Up to like & get recommendations! 0
Published in 2025 at "JAMA Surgery"
DOI: 10.1001/jamasurg.2025.0220
Abstract: Key Points Question Compared with neoadjuvant chemoradiotherapy (NCRT), is neoadjuvant chemoimmunotherapy (NCIT) associated with enhanced tumor regression and long-term survival in patients with locally advanced esophageal squamous cell carcinoma (ESCC)? Findings In this comparative effectiveness… read more here.
Sign Up to like & get recommendations! 0
Published in 2025 at "Advanced science"
DOI: 10.1002/advs.202514332
Abstract: Locally advanced rectal cancer (LARC) presents significant treatment challenges, particularly in microsatellite stable (MSS) patients, who often show limited response to immunotherapy. In these cases, neoadjuvant chemoradiotherapy (neoCRT) followed by surgery remains the recommended approach.… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "British Journal of Surgery"
DOI: 10.1002/bjs.10879
Abstract: It is not clear whether all patients with rectal cancer need chemoradiotherapy. A restrictive use of neoadjuvant chemoradiotherapy (nCRT) based on MRI findings for rectal cancer was investigated in this study. read more here.
Sign Up to like & get recommendations! 0
Published in 2025 at "Cancer Communications"
DOI: 10.1002/cac2.70058
Abstract: The optimal regimen and chemotherapy intensity are still under investigation for neoadjuvant treatment of locally advanced rectal cancer (LARC). The CinClare trial has demonstrated improved pathologic complete response (pCR) with the addition of irinotecan to… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5086
Abstract: Early detection of non‐response to neoadjuvant chemoradiotherapy (nCRT) for locally advanced colorectal cancer (LARC) remains challenging. We aimed to assess whether pretreatment radiotherapy planning computed tomography (CT) radiomics could distinguish the patients with no response… read more here.
Sign Up to like & get recommendations! 0
Published in 2025 at "Cancer Medicine"
DOI: 10.1002/cam4.70676
Abstract: The recurrence patterns of different types of pathologic regression of the primary tumor and lymph nodes in patients with esophageal squamous cell carcinoma (ESCC) after neoadjuvant chemoradiotherapy (NCRT) are little known, especially in ypT0N+ patients. read more here.
Sign Up to like & get recommendations! 0
Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30410
Abstract: Stage II and III rectal cancers have been effectively treated with neoadjuvant chemoradiotherapy (NCRT) followed by definitive resection. Advancements in surgical technique and systemic therapy have prompted investigation of neoadjuvant multiagent chemotherapy (NMAC) regimens with… read more here.
Sign Up to like & get recommendations! 0
Published in 2019 at "Journal of Cellular Biochemistry"
DOI: 10.1002/jcb.27796
Abstract: Radiotherapy plays a crucial role in combined treatment modality in local advanced rectal cancer (LARC). While neoadjuvant chemoradiotherapy responses were variable in LARC patients, so, it is important to identify genes that closely associated with… read more here.
Sign Up to like & get recommendations! 0
Published in 2018 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.24907
Abstract: To evaluate the prognostic significance of neoadjuvant rectal (NAR) score after neoadjuvant chemoradiotherapy (nCRT) for locally advanced rectal cancer (LARC), and to develop a nomogram predicting disease‐free survival (DFS). read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Surgical Oncology"
DOI: 10.1002/jso.26854
Abstract: There is little data on the correlation between the reduction in fluorodeoxyglucose positron emission tomography (FDG‐PET) radioactive accumulation and carbohydrate antigen 19‐9 (CA19‐9) levels with pathological tumor responses (PTRs) and prognosis after neoadjuvant chemoradiotherapy (NACRT)… read more here.